INLX
10/14/26

Intellinetics (INLX)

Wednesday
7:29 PM
ThesisRecent strategic partnerships and product innovations are expected to enhance revenue growth and reduce customer churn, improving investor sentiment.

Revenue Outlook

★ Analysts see FY2026 revenue reaching $19M — +14.6% growth in a single year.

The Bull Case for Growth

  1. 01Recent partnership with a major healthcare provider expected to increase ARR by 15% over the next 12 months.
  2. 02Launch of a new AI-driven feature set that could reduce client churn by 20%.
  3. 03Increased regulatory compliance requirements driving demand for document management solutions.
  4. 04Potential acquisition interest from larger software firms looking to expand into document management.
  5. 05Digital transformation in healthcare
  6. 06Increased focus on data security and compliance
  7. 07Adoption rates of cloud-based document management solutions in healthcare
  8. 08Regulatory changes impacting data management requirements
FY2025 Snapshot
EPS
$-0.44
1Y Return
-60.0%

INLX Chart

4.35.26.27.18.04.70INLX Daily4.70May '26Jul '26Aug '26Oct '26

My Notes

  • "Our focus on compliance-driven solutions positions us well in a rapidly evolving market."
  • Moat: Intellinetics has a moderate moat due to its proprietary technology and established relationships in the healthcare sector.
  • growth - Investors looking for technology companies with potential for scalability and recurring revenue streams.
  • Interest rates affect Intellinetics primarily through the cost of financing for growth initiatives.
  • Watch on earnings: Annual recurring revenue (ARR), Customer retention rate, Churn rate.

One Sentence Summary:

The bull case: Intellinetics is positioned for +14.6% growth on the back of recent partnership with a major healthcare provider expected to increase arr by 15% over the next 12 months.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.